Epigenomics AG
Graf
Godt at vide: Investering i aktier giver typisk et positivt afkast på lang sigt, men indebærer også risiko. Du kan miste dele af eller hele din investering. Tidligere data for denne aktie er ikke en pålidelig indikator for fremtidige afkast. Data fra eksterne udbydere er ikke blevet ændret af Saxo Bank. Se fuld ansvarsfraskrivelse for data.
Om Epigenomics AG
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
/ 